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Abstract
Background: Uricase has proven therapeutic value in treating hyperuricemia but sufficient reduction of its immunogenicity
may be the largest obstacle to its chronic use. In this study, canine uricase was modified with 5 kDa mPEG-SPA and the
impact of large aggregated uricases and cross-linked conjugates induced by difunctional PEG diol on immunogenicity was
investigated.
Methods and Findings: Recombinant canine uricase was first expressed and purified to homogeneity. Source 15Q anion-
exchange chromatography was used to separate tetrameric and aggregated uricase prior to pegylation, while DEAE anion-
exchange chromatography was used to remove Di-acid PEG (precursor of PEG diol) from unfractionated 5 kDa mPEG-
propionic acid. Tetrameric and aggregated uricases were separately modified with the purified mPEG-SPA. In addition,
tetrameric uricases was modified with unfractionated mPEG-SPA, resulting in three types of 5 kDa mPEG-SPA modified
uricase. The conjugate size was evaluated by dynamic light scattering and transmission electron microscope. The influence
of differently PEGylated uricases on pharmacokinetics and immunogenicity were evaluated in vivo. The accelerated blood
clearance (ABC) phenomenon previously identified for PEGylated liposomes occurred in rats injected with PEGylated uricase
aggregates. Anti-PEG IgM antibodies, rather than neutralizing antibodies, were found to mediate the ABC.
Conclusions: The size of conjugates is important for triggering such phenomena and we speculate that 40–60 nm is the
lower size limit that can trigger ABC. Removal of the uricase aggregates and the PEG diol contaminant and modifying with
small PEG reagents enabled ABC to be successfully avoided and sufficient reduction in the immunogenicity of 5 kDa mPEG-
modified tetrameric canine uricase.
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Introduction
Uricase [EC 1.7.3.3] is an enzyme involved in the purine
degradation pathway, that catalyzes the oxidation of uric acid to
allantoin [1]. Humans are devoid of active uricase and the
accumulation of uric acid in blood causes gout symptoms [2].
Recombinant Aspergillus flavus uricase (Rasburicase) has been used
to treat hyperuricemic disorders [3] but the potential immunoge-
nicity limits its long-term use [4]. Pegylated uricase, with low
immunogenicity and a long circulation half-life, has been under
clinical investigation since the 1980s [5]. Most of the uricases used
in pegylation research were from fungal origins [6] and no
PEGylated microbial uricases have become available for further
clinical investigation. However, a PEGylated porcine-like recom-
binant uricase [7] (Pegloticase) has been marketed since Septem-
ber 14, 2010 [8], suggesting that mammalian uricase is more
suitable for developing PEGylated uricase intended for long-term
use. However, 92% of patients developed antibodies and 58% of
patients showed decreased urate-lowing efficacy after repeated
administration during clinical trials of Pegloticase [9,10,11]. The
largest obstacle to clinical use may lie in the sufficient reduction of
the immunogenicity of PEGylated uricases.
Active uricase from all species is a homo-tetramer [12], in
which one-third of the residues are hydrophobic [13], with a
tendency for the tetramers to aggregate to form octomers or
larger aggregates. The high molecular weight aggregates are
highly immunogenic but their contents cannot be judged by
SDS-PAGE or reversed phase-high performance liquid chroma-
tography (RP-HPLC), which can only evaluate the homogeneity
of denatured monomeric uricase. The native aggregated uricase
content is important but has been ignored in most published
papers [6,14,15].
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amount of PEG diol, ranging between 1 and 10% [16], due to
the presence of trace amounts of water during polymerization
[17]. PEG diol is difunctional PEG and could induce unwanted
cross-linked conjugates during subsequent PEG modification [16].
The amount of cross-linked conjugate dramatically increases as the
PEG modification degree increases. In the case of homo-
tetrameric uricase of molecular weight 140 kDa, saturated
pegylation using all accessible e amino sites of lysine residues has
been developed to reduce its immunogenicity [7,18]. Moreover,
the effective dose of PEGylated uricase [19] is much higher than
that of PEGylated cytokines [20]. Taken together, a high
modification degree could increase the rate of cross-linked
conjugates, while higher dosage means more congregates would
be delivered, both of which cause higher immunogenic hazards
than conventional PEGylated proteins. To date, most uricase
pegylation research has concentrated on the structure and size of
the PEG reagent [21,22] and the improvement of enzymatic and
pharmaceutical properties [6,15]. There are few studies on the
potential immunogenic hazards caused by PEG diol-mediated
cross-linked conjugates.
In this study, canine uricase was selected for recombinant
expression and production in E. coli. Tetrameric and large
aggregated recombinant canine uricase (rCU) proteins were
successfully purified and characterized. Prior to PEGylation,
anion-exchange chromatography was used to remove the Di-
acid PEG (precursor of PEG diol). Uricase with or without
aggregates was modified to saturation with purified or unfrac-
tionated 5 kDa mPEG-succinimidyl propionic acid (mPEG-
SPA). The impact of unmodified uricase aggregates and cross-
linked uricase conjugates induced by PEG diol on pharmaco-
kinetics and immunogenicity were studied in vivo. Accelerated
blood clearance (ABC) [23,24,25,26], which usually appears
with PEGylated nanoparticles but rarely emerges in peg-
modified proteins, was confirmed with PEGylated uricase
aggregates. The relationship between ABC and the size of
PEGylated uricase was investigated.
Materials and Methods
Experimental Animals and Ethics Statement
Adult male Sprague-Dawley (SD) rats were obtained from
Shanghai B&K Laboratory Animal Co., Ltd. All the animals were
kept under a natural dark/light cycle and allowed to access food
and water freely. All animal studies were approved by the Animal
Care and Use Committee of Fagen Biomedical Inc. (Approval ID:
FGB-2009-006) and comply with the USDA Animal Welfare Act
,http://www.nal.usda.gov/awic/legislat/usdaleg1.htm. (9 CFR
Parts 1, 2, and 3). The administration of substances and removal of
blood were in compliance with the EFPIA/ECVAM guidelines
issued in 2001 [27].
Construction, Expression and Purification of
Recombinant Canine Uricase (rCU)
A codon-optimized full length canine uricase gene was designed
and synthesized based on the protein sequence of wild-type canine
uricase [28,29]. The canine uricase gene was digested and ligated
into pET-3c. The recombinant plasmids were transferred to host
strain Bl21 Star
TM (DE3) plysS. To express the protein, a single
colony was inoculated into Luria-Bertani medium containing
Figure 1. SDS-PAGE and SE-HPLC analyses of rCU during the
expression and purification process. (A) SDS-PAGE analysis lanes:
M, standard protein molecular weight markers; 1, crude cell extract
before IPTG induction; 2, crude cell extract after IPTG induction for 3
hours; 3, crude extraction in 100 mM sodium carbonate buffer
(pH 10.3); 4, purified rCU after ammonium sulfate fractionation; 5,
purified rCU after xanthine affinity chromatography; 6, purified rCU after
anion exchange chromatography. (B) SE-HPLC analysis: B1 purified rCU
after xanthine affinity chromatography; B2 tetrameric wDU eluted with
0.1 M NaCl on a Source 15 Q column; B3 large aggregated wDU eluted
with 0.25 M NaCl on a Source 15 Q column; a, b and c correspond to
tetramer, octamer and large aggregate, respectively.
doi:10.1371/journal.pone.0039659.g001
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reached 0.6, expression was induced by addition of IPTG to the
final concentration of 0.4 mM for 5 h at 37uC. The cells were
harvested and resuspended in lysis buffers, as described previously
[30]. The suspension was centrifuged and insoluble uricase protein
was extracted into buffers containing 0.2 M Na2CO3, pH10.3. A
10% saturated solution of ammonium sulfate was added to the
supernatant and the target protein was salted out. The protein was
redissolved and loaded onto a xanthine agarose column. Uricase
was eluted with an extraction buffer containing 60 mM xanthine.
Anion-exchange chromatography (SOURCE 15Q 4.6/100 PE)
was then used to separate active uricase isomers. The column was
equilibrated with 0.2 M Na2CO3, pH 10.3. Tetrameric uricase
and larger aggregates were eluted with equilibration buffers
containing 0.1 and 0.25 M NaCl, respectively.
Characterization of rCU
The protein concentration of rCU was determined by the Bio-
Rad protein assay kit, using bovine serum albumin as the protein
standard. The homogeneity and molecular mass of the purified
protein were determined by SDS-PAGE. The isomer forms were
analyzed by size exclusion HPLC (SE-HPLC) equipped with a UV
detector on a Superdex 200 10/300 GL column, which was
equilibrated in 0.1 M Na2CO3, pH 10.3. The sample was eluted
at a flow rate of 0.4 ml/min and detected at 280 nm.
The activity of uricase was measured by the decrease in
absorbance at 290 nm due to enzymatic oxidation of uric acid, as
described previously [31]. Enzyme activity assays were carried out
in 0.1 M sodium borate buffer (pH8.6) at 37uC. An extinction
coefficient of 12,300 M
21 cm
21 for uric acid was used. One unit
(U) of enzyme activity is defined as the amount of enzyme that
catalyzes the oxidation of 1 mmol of uric acid per min at 37uC.
Preparation of Methoxy-PEG-Succinimidyl Propionate
(mPEG-SPA)
Unfractionated dried 5 kDa methoxy-PEG-propionic acid
(mPEG-PA) was kindly provided by Jenkem Technology
(Beijing, China). The unfractionated mPEG-PA was dissolved
in deionized water (5.0 g/L) and purified by DEAE anion-
exchange chromatography, which was equilibrated with deion-
ized water. Pure 5 kDa mPEG-PA without Di-acid PEG (PA-
PEG-PA, precursor of PEG diol) was eluted with deionzied
water containing 10 mM NaCl, and other 5 kDa mPEG-PA
that contained Di-acid PEG was eluted with 20 mM NaCl. The
Di-acid PEG contents were analyzed by SE-HPLC equipped
with a differential refractive index detector on a G2000PWXL
column. Purified mPEG-PA that did not contain Di-acid PEG
was then precipitated in cold diethylether, filtered and dried
over vacuum. Purified and unfractionated mPEG-PA was
further converted to mPEG-SPA as described previously [32]
and stored at 220uC prior to use.
Preparation of mPEG-rCU
Purified canine uricase was reacted with mPEG-SPA 5 kDa in
sodium carbonate buffer (100 mM, pH 10.0) at 4uC for 12 h.
mPEG-SPA 5 kDa (in 4-fold molar excess to the total lysines
present in uricase) dissolved in 10 mM HCl was added to a cold
solution of rCU (4 mg/ml). The conjugation solutions were loaded
onto a Sephacryl S 300 size exclusion column to remove by-
products of PEGylation reactions. The column was pre-equili-
brated and eluted with PBS. Three types of mPEG-rCU were
produced: mPEG-rCU-1 (tetrameric uricase modified with puri-
fied mPEG-SPA), mPEG-rCU-2 (aggregated uricase modified
with purified mPEG-SPA), and mPEG-rCU-3 (tetrameric uricase
modified with unfractionated mPEG-SPA).
Characterization of mPEG-rCU
The activity of modified uricase was assayed as described above.
An Invitrogen NuPAGE
TM gradient 4–12% Bis-Tris gel was used
to determine the homogeneity of mPEG-rCU. The modification
degree (the number of mPEG chain induced in a monomeric
uricase protein) was determined by measuring the remaining
amino groups on the protein able to react with fluorescamine [33].
The molecular weight of monomeric mPEG-rCU was evaluated
by MALDI-TOF. The apparent z-average size (the intensity
weighted mean diameter, derived from Stokes-Einstein equation)
and polydispersity index (PDI, indicator of conjugate distribution
ranging between 0 and 1) of the conjugates were measured by
DLS (Malvern Zetasize Nano S90) at a temperature of 25uC and
an angle of 90u. In order to verify the result of DSL, the
morphology of mPEG-rCU was examined by TEM. The
conjugates were mounted on copper grids, negatively stained with
2% phosphotungstic acid and photographed on a Hitachi H-7500
TEM.
Pharmacokinetic Studies
Eighteen male SD rats were randomly divided into three groups
and intravenously injected with 1.0 mg/kg of mPEG-rCU-1
(group one) or equal protein amounts of mPEG-rCU-2 (group
two) and mPEG-rCU-3 (group three), respectively. Blood samples
were taken by retrobulbar bleeding and collected in heparinized
vials at 1, 24, 48, 72 and 120 h. The plasma was obtained by
centrifugation at 5000 rpm for 10 min. The pharmacokinetics of
mPEG-rCU were determined by measuring the amounts of
plasma uricase activity as described above. Elimination half life (t1/
2z) was calculated in a non compartmental manner based on the
Table 1. Characteristics of unmodified rCU, PEG reagent and PEGylated rCU proteins.
Items mPEG-rCU-1 mPEG-rCU-2 mPEG-rCU-3
Unmodified uricase properties Tetramer content .99.8% 9.8% .99.8%
Enzymatic activity(U/mg) 11.260.6 9.360.4 11.260.6
PEG reagent properties PEG Diol content ,0.2% ,0.2% 2.7%
PEGylated uricase properties Modification degree
a 9.960.5 9.760.6 10.360.6
Enzymatic activity(U/mg) 9.860.7 6.760.5 9.660.6
Enzymatic retention 87.5%65.6% 72.0%64.6% 85.7%66.3%
amodification degree: number of 5 kDa mPEG chains that coupled to each uricase monomer.
doi:10.1371/journal.pone.0039659.t001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39659Figure 2. SE-HPLC analysis of purified and unfractionated mPEG-PA. The PEG diol contents were analyzed using a G2000PWXL column with
a differential refractive index detector. (A) Purified mPEG-PA; (B) Unfractionated mPEG-PA. a and b correspond to Di-acid PEG and mono-acid mPEG.
doi:10.1371/journal.pone.0039659.g002
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(DAS ver 2.0).
Immunological Studies
Twenty-four male SD rats were randomly divided into three
groups and intravenously injected weekly with 1.0 mg/kg of the
three types of mPEG-rCU as described above. Blood samples were
collected at 24 h before and after every injection. The serum
samples collected before each of four weekly injections were used
to determine the antibody amounts. The plasma samples collected
after injections were used to determine the pharmaceutical
properties.
The amount of IgM and IgG antibodies were measured by
enzyme-link immunoassay (ELISA) [34]. Briefly, microtiter plates
were treated overnight at 4uC with 250 mlo f5 0mg/ml of mPEG-
rCU-1, rCU or mPEG-BSA (BSA was modified to saturation with
5 kDa mPEG-SPA and then purified by size-exclusion chroma-
tography) in coating solution (0.1 M NaHCO3, pH 9.5). All wells
were washed and blocked with 3% BSA in PBS for 2 h at 37uC.
Next, the wells were washed and serial dilutions of the serum
samples (in PBS) were added to the wells. The plates were
incubated for 1 h at 37uC and washed with PBS. Peroxidase
conjugated-rabbit anti-rat IgG or IgM diluted 1:2500 in PBS was
added to the wells and the plates were incubated for 1 h at 37uC.
The wells were washed and 100 ml of O-phenylenediamine
peroxidase substrate solution was added. The enzymatic reaction
was stopped after 30 min by addition of 50 ml/well of 2 N sulfuric
acid and the absorbance at 490 nm was determined.
To determine if the immune response was neutralizing, the rat
anti-serum samples were serially diluted in PBS and incubated
with mPEG-rCU-1 for 2 h at 37uC. The enzyme activity was then
determined, as described above.
Results
Expression, Purification and Analysis of rCU
The gene coding for canine uricase was synthesized and fused
into pET3c, resulting in the construction of pET3c-rCU. The
recombinant enzyme was produced upon induction with IPTG in
Bl21 Star (DE3) plysS. As shown in Figure 1A, the amount of
synthesized rCU was approximately 35% of the total cellular
protein as judged by SDS-PAGE. After ammonium sulfate
fractionation, the recovery of total uricase activity was higher
than 85% but the recovery of uricase protein (determined by RP-
HPLC) was only 34%, suggesting that inactive uricase isomers
(such as monomeric uricase) may exist in the initial extractions, but
most of them could not be redissolved after ammonium sulfate
Figure 3. Representative chromatogram of mPEG-rCU purification The three different chromatograms correspond to mPEG-rCU protein (A),
unconjugated mPEG (B) and N-hydroxysuccinimide acid (C), respectively.
doi:10.1371/journal.pone.0039659.g003
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impurities and inactive uricase isomers. The homogeneity of
purified rCU was greater than 95% as judged by SDS-PAGE and
RP-HPLC [29]. However, SE-HPLC analysis showed that several
kinds of active isomers existed (Figure 1B). A Source 15Q column
was used to purify the active tetrameric uricase following elution
with equilibration buffer containing 0.1 M NaCl. The ratio of the
tetramer was greater than 99%, with the above purification
method removing most impurities and separating uricase isomers.
Enzymatic activity of tetrameric uricase (11.2 U/mg) was higher
than that of larger aggregates (9.3 U/mg), eluted with 0.25 M
NaCl on the Source 15 Q column, as determined at 37uC, pH 8.6
(Table 1).
Modification and Purification of mPEG-rCU
Based on the differences in their electostatic charge, anion-
exchange chromatography was used to remove the Di-acid PEG
from the mono-acid mPEG. Di-acid PEG bound more tightly to
the anion-exchange column than the mono-acid form. As shown
in Figure 2, the content of Di-acid PEG in purified mPEG-PA
was lower than 0.2%, as measured by SE-HPLC, whereas the
amount in the initial, unfractionated 5 kDa mPEG-PA was
about 2.7%. Both purified and unfractionated mPEG-PA were
then converted to 5 kDa mPEG-SPA. Following modification,
tetrameric and aggregated rCU were separately modified with
the purified mPEG-SPA. A further sample of tetrameric rCU
was also modified by unfractionated mPEG-SPA, resulting in
three types of mPEG-rCU, as shown in Table 1. The three
conjugates were further purified by size exclusion chromatog-
raphy (Figure 3). By-products of PEGylation reactions (e.g.
unconjugated PEG and N-hydroxysuccinimide acid) were
efficiently removed (for detailed information see material S1).
RP-HPLC and SE-HPLC showed that only a single peak
existed after the above purification.
Characterization of mPEG-rCU
A more detailed characterization of 5 kDa mPEG modified
canine uricase was presented in a previous study [18]. The
results of SDS-PAGE (Figure 4) show that the molecular weight
of denatured monomeric mPEG-rCU-1 ranged between 110
and 260 kDa. Such a wide range of molecular weights is higher
than the molecular weight of monomeric mPEG-rCU deter-
mined by MALDI-TOF (80–90 kDa; for detailed information
see material S2) and may be caused by the interference with
protein mobility by the coupled mPEG [18]. It should be noted
that different SDS-PAGE behaviors among mPEG-rCU-1,
Figure 4. SDS-PAGE analysis of purified mPEG-rCU. Lanes 1, 2
and 3 represent mPEG-rCU-1, mPEG-rCU-2 and mPEG-rCU-3. A, B and C
correspond to non-crosslinked PEGylated monomeric rCU, crosslinked
conjugates between two PEGylated monomeric rCU, and crosslinked
conjugates among three and more PEGylated monomeric rCU,
respectively.
doi:10.1371/journal.pone.0039659.g004
Figure 5. Representative transmission electron micrograph of mPEG-rCU. (A), (B) and (C) represent mPEG-rCU-1, mPEG-rCU-2 and mPEG-
rCU-3.The magnification is 1000006, scale bar: 200 nm. a, b and c may correspond to PEGylated tetrameric uricase, PEGylated aggregated uricase,
and cross-linked conjugates induced by PEG diol, respectively.
doi:10.1371/journal.pone.0039659.g005
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related to the cross-linked conjugates induced by difunctional
PEG diol. No cross-linked conjugates were present in mPEG-
rCU-1, resulting in higher protein mobility, whereas cross-linked
conjugates were observed in mPEG-rCU-3, as expected, which
may have resulted from two or more cross-linked monomers,
causing lower protein mobility (for detailed information see
material S3). Moreover, the content of cross-linked conjugates in
mPEG-rCU-2 was slightly higher than in mPEG-rCU-1,
suggesting that unmodified uricase aggregates could increase
the cross-linking caused by the low residual amount of PEG diol
(,0.2%). The average extents of modification were similar
among the three product species (Table 1). About 9–10 5 kDa
mPEG chains were coupled to each uricase monomer,
suggesting that there was little impact of uricase aggregation
and PEG diol on modification characteristics. The enzymatic
retentions of mPEG-rCU-1 and mPEG-rCU-3 were higher than
85.0%, whereas that of mPEG-rCU-2 was only 72.0%,
indicating that unmodified uricase aggregates could affect
enzymatic retention during PEGylation.
The size distribution of the three conjugates was measured by
DLS. Only one peak was observed in all three mPEG-rCUs
because of the lack of baseline resolution (data not shown) [35] so
it is difficult to distinguish different populations. The main
differences were the apparent z-average size and PDI values.
The z-average sizes of mPEG-rCU-1, mPEG-rCU-2, mPEG-
rCU-3 were 17.68, 38.56, and 22.38 nm, respectively. The PDI of
mPEG-rCU-1 was 0.062, confirming the good particle uniformity
of 5 kDa mPEG modified tetrameric uricase, whereas the PDI of
mPEG-rCU-2 and mPEG-rCU-3 were 0.519 and 0.287, indicat-
ing that a broad size distribution could be induced by large
aggregated uricase and cross-linked uricase conjugates. To
compare the morphological diversity, each conjugate was sepa-
rately examined by TEM. As shown in Figure 5, homogeneous
particles with diameters of about 14–18 nm (indicated by ‘a’ in
Figure 5A) were observed in mPEG-rCU-1, which may corre-
spond to 5 kDa mPEG modified tetrameric uricase. Many larger
particles with diameters from 30 to 50 nm (indicated by ‘b’ in
Figure 5B), which may correspond to aggregated conjugates, were
observed in mPEG-rCU-2, whereas only a small number of large
particles were observed in mPEG-rCU-3 and most of the particle
size was essentially the same as that in mPEG-rCU-1.
Pharmacokinetic Studies
Rats were used as an experimental model to evaluate the
pharmacokinetics of mPEG-rCU. Note that the known effective
human dose for PEGylated uricase is about 1.0–2.0 U/kg [18,19].
We estimated 0.2 mg/kg (2.0 U/kg) as the effective dose of
mPEG-rCU for individual humans. Therefore, a dose of 1.0 mg/
kg was used for the rats, which were intravenously injected with
the three different mPEG-rCUs, as described above. The time
course profiles obtained by enzymatic activity determination in
plasma are depicted in Figure 6. The elimination half-lives for
mPEG-rCU-1, mPEG-rCU-2, mPEG-rCU-3 were 26.8, 24.8 and
20.1 h, respectively, indicating that large aggregated uricases and
cross-linked conjugates induced by PEG diol did not dramatically
affect the circulation half-life after the first injection.
Repeated injection experiments showed that there was no
change in multiple pharmacokinetic properties of rats in group one
(administered with mPEG-rCU-1) during the next three repeat
injections (Figure 7A). In contrast, the circulatory enzymatic
activities of five rats (Figure 7B) in group two (administered with
mPEG-rCU-2) were lost rapidly after the second injection and the
disappearance rates of enzymatic activities increased with the next
repeated injection. Only one rat in group three (administered with
mPEG-rCU-3) showed rapid loss of enzymatic activity (RLEA)
after the second injection (Figure 7C). No new rats in groups two
and three displayed rapid loss of enzymatic activity during later
injections.
mPEG-rCU-1 was injected into the rats of group two, which
had displayed RLEA prior to this injection. A similar RLEA
phenomenon was also observed (data not shown), indicating that
Figure 6. Time courses of plasma uricase activity in three groups after intravenous administration of mPEG-rCU (n=6).
doi:10.1371/journal.pone.0039659.g006
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could also influence the circulation of normal tetrameric mPEG-
rCU.
Immunological Studies
No difference in enzymatic activity was observed after
incubating mPEG-rCU with anti-serum obtained from all three
administration groups and PBS, suggesting that no neutralizing
antibodies were found in any of the rats during the four injections
of mPEG-rCUs and that the RLEA was not related to neutralizing
antibodies.
The serum levels of IgG and IgM antibodies reactive to mPEG-
rCU after every repeat injection were measured by ELISA. A
screening ELISA performed on 1:50 and 1:100 dilutions failed to
detect IgM and IgG antibodies against mPEG-rCU-1. The next
screening was performed at 1:10 dilutions of plasma. As shown in
Figure 8, no obvious IgG antibodies were observed in either the
normal rats or those that displayed RLEA during the four
injections, suggesting that the RLEA was not mediated by anti-
mPEG-rCU IgG antibodies. However, there were significant
differences in the amounts of anti-mPEG-rCU IgM antibodies
measured between the normal rats in group one and the rats in
group two, which displayed RLEA (Figure 9A). The amount of
IgM antibody reactive to mPEG-rCU in all cases reached its
maximum level before the second injection (at day 7) and
decreased in later injections. Only the rats in group two that
displayed RLEA gave a positive response during the injections
(where anti-mPEG-rCU IgM was regarded as positive if the
optical density at 490 nm wavelength (OD490) was more than 2.1
times that of the same rats before injection). The amounts of IgM
antibody in group one rats showed a slight increase but they
nevertheless showed a negative response after the first injection.
Similarly positive IgM antibodies were observed in one rat of
group three, which also showed RLEA (data not shown).
Another experiment was carried out to specify the anti-mPEG-
rCU antibodies. The amounts of IgM antibody against rCU
proteins and mPEG were evaluated by using rCU and mPEG-
BSA, respectively, for ELISA microplate coating. As shown in
Figure 9B, no positive IgM antibodies were observed by coating
rCU and there were no significant differences in OD490 between
the rats with and without RLEA, indicating that the protein
portion of mPEG-rCU did not react with the anti-mPEG-rCU
IgM antibodies. In contrast, positive IgM antibodies were
observed by coating mPEG-BSA for rats that showed RLEA
(Figure 9C), whereas the rats without RLEA still displayed a
negative response, suggesting that the positive IgM antibody
observed in group two was against mPEG portion of mPEG-rCU.
Discussion
Recombinant canine uricase was expressed and purified to
homogeneity. Several forms of rCU existed in the extraction
buffers. The monomers were inactive forms that could be easily
separated by ammonium sulfate fractionation and affinity chro-
matography. The octameric uricase and larger aggregates were
active isomers, which could only be detected by SE-HPLC. In this
study, tetrameric and larger aggregated rCU were successfully
evaluated and separated.
PEGylation has been successfully used to enhance the thera-
peutic potential of many proteins. The molecular mass of
unmodified uricase is about 140 kDa, while proteins whose
molecular mass exceeds 100 kDa are efficient inducers of immune
responses [36]. The larger the PEG used in modification, the more
the opportunities that may arise to trigger immune responses. The
currently marketed PEGylated uricase (Pegloticase) is modified
with 10 kDa mPEG and the average molecular weight is
approximately 540 kDa [9], which may explain why 92% of
patients developed antibodies against it [9]. Moreover, because the
Figure 7. Retention of plasma uricase activity in three groups
after different injections of mPEG-rCU. Plasmas were collected 24
hours after each of four weekly injections of mPEG-rCU. *, ** and ***
mean significantly different from the same rats before injection at levels
of p,0.05, p,0.01, and p,0.001.
doi:10.1371/journal.pone.0039659.g007
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using 5 kDa mPEG may reduce the generation of anti-PEG
antibodies and lower the overall immunogenicity of PEGylated
uricase. Therefore, 5 kDa mPEG, which has been used in the
manufacture of several commercial PEGylated proteins
[37,38,39], was selected for further investigation in this research.
Low enzymatic retention was the largest obstacle in developing a
5 kDa PEG modified uricase [22,40]. In this study, the enzymatic
retention of PEGylated tetrameric rCU was higher than 85.0%,
whereas that of PEGylated rCU aggregates was only 72.0%,
suggesting that large isomers could affect enzymatic retention but
the impact could be resolved after removing the aggregates.
Commercially available mPEG contains a considerable amount
of PEG diol, which may yield unwanted cross-linked conjugates.
The amount of cross-linked isomers induced by PEG diol could
increase dramatically with an increasing degree of modification.
The theoretical maximum amounts of cross-linked conjugates may
be calculated by the following equation:
C=2 6the number of PEGs coupled per protein6PEG diol
content.
Supposing that the amount of PEG diol is 2%, when a
protein is coupled with only one polymer chain, the maximum
content of cross-linked protein may reach 4%; whereas, in the
case of highly PEGylated uricase, where one monomeric uricase
is coupled with 9–10 5 kDa mPEGs, the theoretical maximum
amount of cross-linked protein may reach 40%. Removing PEG
diol is important for developing homogeneous mPEG-rCU.
mPEG-SPA is unstable in water and there is no mechanism for
removing PEG diol from the activated mPEG reagents [41]. On
the contrary, mPEG-PA is a stable intermediate formed during
the activation step. Anion-exchange chromatography was
successfully used to remove Di-acid PEG-PA from the mono-
acid mPEG-PA in this study.
The improvement of the optimized PEGylated uricase and the
impact of uricase aggregates and cross-linked conjugates on
pharmaceutical and immunological properties were investigated
using rats. Rapid loss of enzymatic activity was observed in rats
injected with mPEG-rCU-2 and mPEG-rCU-3 after the second
injection, indicating that both uricase aggregates and cross-linked
conjugates could trigger immune responses and influence phar-
macokinetics. Moreover, the impact of large aggregated uricase
was larger than cross-linked conjugates, as indicated by the
different occurrence rates of such phenomena between rats
administered with mPEG-rCU-2 and mPEG-rCU-3. No neutral-
izing antibodies were detected in the animals, indicating that the
RLEA is caused by accelerated clearance from circulation. The
difference in serum levels of IgM antibodies between the rats in
group one and the rats displaying rapid elimination in group two
indicates that IgM antibodies are responsible for the RLEA after
repeated injections. Moreover, based on the specificity of anti-
conjugate IgM antibodies, we speculated that the RLEA is
induced by anti-PEG IgM antibodies.
The accelerated blood clearance phenomenon has previously
been observed upon repeated injection of PEGylated liposomes
[25,26,42,43]. The apparent time of the RLEA and the changes
in properties of the IgM antibodies observed here were
consistent with those observed in PEGylated liposomes. Thus,
we speculated that the mechanism causing the RLEA is the
same as that causing ABC. However, previous studies have
shown that the mechanism(s) for inducing such behavior are still
not entirely clear. The hypothesis proposed is that this behavior
involves sequential steps, including induction of anti-PEG IgM
antibody production in the spleen with the first dose of
PEGylated conjugates, complement activation by the IgM
antibody and opsonization by C3 fragments following the
second dose of PEGylated conjugates, and their uptake by the
mononuclear phagocyte system [24,44,45,46].
The ABC phenomenon is generally induced by PEG-
modified nanoparticles but a similar phenomenon was first
confirmed in PEGylated proteins. Earlier reports demonstrated
that various factors, such as dose, size and peg-surface density,
could influence the magnitude of the ABC [23] but strategies to
Figure 8. ELISA analysis of IgG antibody against mPEG-rCU. Serum samples were collected 24 hours before each of four weekly injections of
mPEG-rCU. Microtiter plates were coated with 50 mg/ml of mPEG-rCU-1.
doi:10.1371/journal.pone.0039659.g008
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PEGylated liposomes and uricase include the large size of the
conjugates. The z-average size of 5 kDa mPEG-modified
tetrameric uricase calculated by DLS (17.68 nm) agreed
essentially with that evaluated by TEM (14–18 nm). Although
the z-average size of mPEG-rCU-2 was only 38.56, the size of
large aggregates in mPEG-rCU-2 caused by aggregation of
several tetrameric uricase constructs may increase several times
and reach 60 nm, which is consistent with the size of small
PEGylated liposomes [47] that can effectively manifest such
behavior. On the contrary, PEGylated tetramer conjugates
apparently could not induce ABC behavior (rats in group one).
In addition, most of the cross-linked conjugates induced by PEG
diol were aggregates between two tetramers, whose size may
reach 30–40 nm but are less efficient in triggering that behavior
(rats in group three). The above observations indicate that the
conjugate size is of primary importance in inducing the ABC
phenomenon, which is consistent with the results reported by
Koide et al [48,49]. To be more precise, we speculate that 40–
60 nm is the lower size limit that can trigger ABC. PEGylation
cannot induce ABC when the size of the PEGylated protein is
under this lower limit and this may explain why ABC is not
widely found in PEGylated proteins. However, for uricase,
native aggregates and cross-linked conjugates may attain the
lower size limit and high usage may then ensure the dose is
sufficient to induce ABC.
Although the uricase origin (canine) used in this study differs
from that of Pegloticase (porcine), the amino acid identity between
porcine and canine uricase is higher than 90%. Moreover, the
immunogenicity of native uricase could be sufficiently reduced by
PEGylation. Thus, it is likely that uricases from different
mammalian origin differ little in their influence on immunogenic-
ity. The Stokes’ radius of native tetrameric uricase is 42.7 A ˚ [21],
while the particle size reached 14–18 nm after modification with
5 kDa mPEG, which is approximately 2–3 times larger than the
native form and is in good agreement with the results reported by
Efremova et al. that modification with 5–6 kDa mPEG could
create a polymer layer thickness of 4–10 nm [50]. The size may
increase 4–10 times by modification with 10 kDa or 20 kDa
mPEG, and may thus reach the lower size limit that can trigger
ABC. Since the a similar decreased urate-lowering efficacy after
repeated administrations observed during clinical trials of Pegloti-
case, which is modified by 9–10 10 kDa mPEG chains per
monomer, we hope that our findings in rats may help to explain
the decreased urate-lowering efficacy of Pegloticase in clinical
practice. However, further investigation is required to provide
direct evidence.
It should also be noted that ABC, triggered by larger aggregates,
could also influence the circulation of the smaller PEGylated
uricase, suggesting that if we wish to avoid such behavior, larger
sized conjugates should be sufficiently removed. Previous studies
ignored this behavior and this may have prevented further
development of PEGylated uricase for clinical use. In this study,
we used anion exchange chromatography to remove uricase
aggregates and to purify 5 kDa mPEG-SPA. After removing the
uricase aggregates and the PEG diol contaminant and modifying
with small PEG reagents, the size of the mPEG-rCU remained
below the lower limit that can trigger ABC, thus successfully
avoiding ABC. Furthermore, the optimized conjugates stimulated
few IgM and IgG antibodies after four injections, indicating the
effective reduction of immunogenicity. Further chronic toxicity
and immunogenicity assessments in rodents and non-human
primates are currently underway in our laboratory, with the
ultimate goal of bringing the PEGylated uricase to a successful
clinical application.
Figure 9. ELISA analysis of IgM antibody against mPEG-rCU,
rCU, or mPEG-BSA Serum samples were collected 24 hours before
each of four weekly injections of mPEG-rCU. (A) Microtiter plates were
coated with 50 mg/ml of mPEG-rCU-1. (B) Microtiter plates were coated
with 10 mg/ml of tetrameric rCU. (C) Microtiter plates were coated with
50 mg/ml of mPEG-BSA.
doi:10.1371/journal.pone.0039659.g009
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